ethyl (E)-3-(5-bromothiophen-2-yl)acrylate | 151451-43-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (E)-3-(5-bromothiophen-2-yl)acrylate
• 英文别名: Ethyl 3-(5-bromothiophen-2-yl)acrylate；ethyl (E)-3-(5-bromothiophen-2-yl)prop-2-enoate
• CAS: 151451-43-3
• 化学式: C₉H₉BrO₂S
• 分子量: 261.139
• InChiKey: JAVFXFRTSHFVJE-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (E)-3-(5-bromothiophen-2-yl)acrylate 在 氢氧化钾 作用下， 生成 (2E)-3-(5-溴(2-噻吩))-2-丙烯酸
  参考文献：
  名称：

  STUDIES IN THE THIOPHENE SERIES. VII.¹ THE APPLICATION OF THE REFORMATSKY REACTION TO THIOPHENE ALDEHYDES AND KETONES

  摘要：

  DOI：

  10.1021/jo01147a015
• 作为产物：
  描述：

  5-溴噻吩-2-甲醛 、 乙氧甲酰基亚甲基三苯基膦 以 苯 为溶剂， 反应 7.0h， 以80%的产率得到ethyl (E)-3-(5-bromothiophen-2-yl)acrylate
  参考文献：
  名称：

  3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies

  摘要：

  Baclofen (beta-(p-chlorophenyl)-GABA) is a selective agonist for the bicuculline-insensitive GABA(B) receptor. The search for new compounds that bind to the GABA(B) receptor is very important to clarify structural requirements. We report herein the synthesis and the binding studies of variously substituted 3-thienyl- and 3-furylaminobutyric acids. 4-Amino-3-(5-methyl-2-thienyl)butyric acid (5d) and 4-amino-3-(5-chloro-2-thienyl)butyric acid (5h) are potent and specific ligands for GABA(B) receptor. The IC50 values for the displacement of (R)-(-)-[H-3]baclofen are 1.34 and 0.61-mu-M for 5d and 5h, respectively, as compared to 0.33-mu-M for baclofen.

  DOI：

  10.1021/jm00112a033

文献信息

• Asymmetric Aminohydroxylation of Heteroaromatic Acrylates
  作者：Dirk Raatz、Clara Innertsberger、Oliver Reiser

  DOI：10.1055/s-1999-2973

  日期：1999.12

  N-, S- and O-heteroaromatic acrylates were aminohydroxylated with generally high regio- and enantioselectivity. While pyridylacrylates are not amenable towards this process, the corresponding N-oxides proved to be a useful substitute, allowing the access to biologically important pyridine substituted taxolTM side chain analogs.

  N-、S-和O-杂 heteroaromatic 丙烯酸酯以通常较高的区域选择性和对映选择性进行了氨基羟基化。虽然吡啶丙烯酸酯不适合此过程，但相应的N-氧化物证明是一个有用的替代品，使得获得生物重要的吡啶取代的紫杉醇侧链类似物成为可能。
• Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030134849A1

  公开（公告）日：2003-07-17

  A compound of formula (I) in which R 1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R 2 is amidated carboxy, R 3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).

  式(I)的化合物，其中R1是卤素、低碳氧基、可选取代芳基、可选取代芳氧基、可选取代杂环基或可选取代低炔基，R2是酰胺化羧基，R3是氢或酰基，Ar是芳基或杂环基，X是硫代、亚砜基或磺酰基，Y和Z是各自的低碳链基，m和n分别是0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）抑制剂或肿瘤坏死因子α（TNFα）的产生。
• [EN] THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE L'ACIDE THIAZEPINYLHYDROXAMIQUE EN TANT QU'INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001060808A1

  公开（公告）日：2001-08-23

  A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor α (TNF α).

  化合物的化学式为（I），其中R1为卤素，较低的烷氧基，可选取代芳基，可选取代芳氧基，可选取代杂环基或可选取代较低的炔基，R2为酰胺化的羧基，R3为氢或酰基，Ar为芳基或杂环基，X为硫代基，亚砜基或磺酰基，Y和Z均为较低的烷基，m和n均为0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）或肿瘤坏死因子α（TNFα）的抑制剂。
• Anilide derivative, production and use thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06413947B1

  公开（公告）日：2002-07-02

  This invention is to provide a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an, optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.

  这项发明提供了一种化合物，其化学式为：其中R1是可选择性地取代的5-至6-成员环；W是下列化学式的二价基团：其中环A是可选择性地取代的5-至6-成员芳香环，X是可选择性地取代的C、N或O原子，环B是可选择性地取代的5-至7-成员环；Z是化学键或二价基团；R2是（1）可选择性地取代的氨基基团，其中氮原子可以形成季铵盐等，或其盐，用于拮抗MCP-1受体。
• Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06268354B1

  公开（公告）日：2001-07-31

  This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof.

  本发明提供了一种用于拮抗CCR5的药物组合物，其包括式中的化合物：其中R1是可选取的取代的5-至6-成员环；W是式的双价基团：其中环A是可选取的取代的5-至6-成员芳香环，X是可选取的取代的C、N或O原子，环B是可选取的取代的5-至7-成员环；Z是化学键或双价基团；R2是(1)可选取的取代氨基团，其中氮原子可形成季铵盐等，或其盐。